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Introduction
Platelet-derived growth factor receptor α (PDG FRα) is a recep-
tor tyrosine kinase that controls a series of cellular processes, 
including proliferation, survival, migration, and differentiation, 
in turn affecting development and tissue homeostasis of several 
organs. Consequently, aberrant PDG FRα signaling contributes 
to the pathophysiology of various diseases and developmental 
disorders, such as fibrotic diseases, tumorigenesis, and cancer 
(Olson and Soriano, 2009; Demoulin and Montano-Almendras, 
2012; Heldin and Lennartsson, 2013; Demoulin and Essaghir, 
2014; Velghe et al., 2014; Farahani and Xaymardan, 2015).
PDG FRα localizes to, and is activated at, the primary 
cilium in a variety of cell types (Christensen et al., 2017). In 
fibroblasts, ciliary PDG FRα signaling involves the activation 
of AKT and ERK1/2 at the ciliary base to control directional 
cell migration (Schneider et al., 2005, 2009, 2010; Clement et 
al., 2013). PDG FRα is up-regulated during concomitant growth 
arrest and formation of the primary cilium, and up-regulation 
and activation of the receptor by PDGF-AA are blocked in cy-
cling cells and in growth-arrested mouse embryonic fibroblasts 
lacking intraflagellar transport (IFT) proteins IFT88 (Schnei-
der et al., 2005) or IFT172 (Umberger and Caspary, 2015), 
which are part of the IFT-B subcomplex required for ciliogen-
esis (Taschner et al., 2016). These findings indicate that the 
basal pool of PDG FRα in cycling cells is not accessible at the 
plasma membrane for ligand-mediated receptor activation but 
needs to be localized to the cilium for normal signal transduc-
tion. However, the mechanisms by which PDG FRα localizes 
to the primary cilium and how the level of PDG FRα signaling 
at the cilium is properly balanced by feedback inhibition after 
ligand-induced activation of the receptor are unknown.
To study the mechanisms that regulate sorting and feed-
back inhibition of ciliary PDG FRα signaling, we investigated 
the role of IFT20, which is part of the ciliary IFT-B subcomplex 
(Cole et al., 1998; Taschner et al., 2016). In addition, IFT20 lo-
calizes to the Golgi compartment to promote vesicular transport 
of selected transmembrane proteins, including polycystin-2 and 
opsin, to the primary cilium (Follit et al., 2006, 2008; Keady 
et al., 2011). IFT20 has also been assigned extraciliary func-
tions, such as organization of the polarized trafficking of T cell 
receptors (TCRs) to the immune synapse (Finetti et al., 2009, 
2014; Vivar et al., 2016) and trafficking procollagen from the 
endoplasmic reticulum to the Golgi in osteoblasts (Noda et al., 
2016). To study the function of IFT20 in regulating PDG FRα 
signaling, we generated an NIH3T3-based cell line that allows 
conditional silencing of IFT20 by doxycycline (Dox)-inducible 
expression of a shRNA targeting mouse IFT20 (NIH3T3shIFT20). 
Using this approach, in which the expression of IFT20 can be 
down-regulated in a controlled manner, we identified IFT20 
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as a novel regulator of ciliary signaling, which interacts with 
E3 ubiquitin ligases c-Cbl and Cbl-b that mediate ubiquitina-
tion and internalization of PDG FRα for feedback inhibition of 
receptor signaling. IFT20 exerts its effect through the stabili-
zation of the Cbl proteins, which, in the absence of IFT20, un-
dergo autoubiquitination and proteasomal degradation, leading 
to aberrant PDG FRα signaling.
Results and discussion
Conditional silencing of IFT20 leads  
to defects in feedback inhibition of 
PDG FRα signaling
To investigate the role of IFT20 in regulating PDG FRα signal-
ing, we first depleted IFT20 by Dox treatment of NIH3T3shIFT20 
cells (Fig. 1 a), which led to undetectable levels of IFT20 pro-
tein after 3 d of treatment, as assessed by Western blot (WB; 
Fig. 1 b) and immunofluorescence microscopy (IFM) analyses 
(Fig. 1, c and d). Dox-mediated IFT20 knockdown significantly 
decreased the frequency of ciliated cells (Fig.  1, e and f), as 
expected (Follit et al., 2006, 2008; Keady et al., 2011), whereas 
untreated NIH3T3shIFT20 cells displayed normal ciliation fre-
quencies (∼60%; Fig. 1 f; Schneider et al., 2005) and showed 
WT localization of IFT20 at the cilium and at the Golgi com-
plex (Fig. 1, c–e). The Golgi complex was not grossly disturbed 
in NIH3T3shIFT20 cells treated with Dox, as revealed by staining 
for giantin (Fig. 1 d). To monitor how IFT20 affects the strength 
and kinetics in feedback inhibition of PDG FRα signaling, we 
next subjected growth-arrested NIH3T3shIFT20 cells to PDGF-AA 
stimulation for an expanded interval (0–240 min). Interestingly, 
IFT20-depleted cells displayed a dramatically amplified and 
prolonged phosphorylation of PDG FRα, AKT, and ERK1/2 as 
compared with control cells (Fig. 1, g and h), suggesting that 
feedback inhibition of PDG FRα signaling is impaired in those 
cells. Importantly, Dox treatment itself did not elicit changes in 
PDG FRα signaling in WT NIH3T3 cells (Fig. S1, a and b), and 
we furthermore found that stable expression of a GFP-tagged 
IFT20 allele, resistant to the IFT20 shRNA (NIH3T3shIFT20-Res; 
Fig. 1, i and j), rescued the ciliogenesis (Fig. 1 j) and PDG FRα 
signaling defects in Dox-treated NIH3T3shIFT20 cells (Fig. 1, k 
and l), substantiating the conjecture that IFT20 is required for 
proper feedback inhibition of signaling. Our results also showed 
that up-regulation of PDG FRα expression during growth arrest 
(Schneider et al., 2005) is not affected by IFT20 depletion (Fig. 
S1 c). This is in sharp contrast to the reduced PDG FRα levels 
observed in cells lacking IFT88 (Fig. S1 d; Schneider et al., 
2005). Thus, IFT20 is essential for proper feedback inhibition 
of PDG FRα signaling but is not essential for up-regulation and 
activation of the receptor during growth arrest.
IFT20 is required for ubiquitination and 
internalization of PDG FRα
We noticed that overactivation of PDG FRα signaling in Dox-
treated NIH3T3shIFT20 cells was associated with a prominent re-
duction in posttranslational modification (PTM) of PDG FRα, 
as indicated by a major reduction in a high–molecular-weight 
smear appearing after 10, 30, and 90 min of PDGF-AA stim-
ulation (Fig. 1 g). Because PTM, in response to ligand stimu-
lation, is a distinctive sign of RTK ubiquitination, which leads 
to internalization and down-regulation of signaling (Coats et 
al., 1994; Mori et al., 1995), we next monitored the covalent 
attachment of endogenous or Myc-tagged ubiquitin to PDG FRα 
by immunoprecipitation (IP) in NIH3T3shIFT20 cells stimulated 
with PDGF-AA for 10 min in the absence or presence of Dox. 
The results revealed a prominent reduction in receptor polyubi- 
quitination in IFT20-depleted cells (Fig.  2  a), demonstrat-
ing that IFT20 is required for proper receptor ubiquitination. 
In support of that conclusion, restoration of normal PDG FRα 
signaling in Dox-treated NIH3T3shIFT20-Res cells was similarly 
associated with restoration of PTM in PDG FRα (Fig.  1  k), 
and the activated receptor in Dox-treated, WT NIH3T3 cells 
displayed neither reduced PTM (Fig. S1 a) nor reduced ubiq-
uitination (Fig. S2 a).
To further examine whether reduced ubiquitination of 
PDG FRα in IFT20-depleted cells is accompanied by reduced 
internalization of the receptor, PDG FRα was biotin-labeled 
using membrane-impermeable EZ-Link Sulfo-NHS-SS-Biotin 
reagent before or after addition of PDGF-AA. Biotin-labeled 
proteins were enriched by pull-down with streptavidin beads, 
followed by WB analysis with an antibody against PDG FRα. 
In the absence of the ligand, the level of biotinylated receptor 
at the cell surface and in internalized vesicles was similar in 
NIH3T3shIFT20 cells with or without Dox treatment. Upon ad-
dition of PDGF-AA, removal and internalization of PDG FRα 
from the cell surface was significantly delayed in cells lack-
ing IFT20 (Fig. 2, b and c). Together, these findings indicate 
that IFT20 is important for ubiquitination and internalization of 
PDG FRα for proper feedback inhibition of PDG FRα signaling.
Silencing of IFT20 promotes 
autoubiquitination and proteasomal 
degradation of Cbl proteins
Overactivation of PDG FRα and markedly reduced PDG FRα 
polyubiquitination and internalization upon ligand stimulation 
in IFT20-deficient cells point to a crucial function of IFT20 in 
establishing a competent E3-ubiquitin ligase-dependent, neg-
ative feedback mechanism in PDG FRα signaling. Because 
PDGF receptors are bona fide substrates of two proximal 
RING finger E3-ubiquitin ligase paralogs, designated as c-Cbl 
and Cbl-b (Bonita et al., 1997; Miyake et al., 1998; Mohapa-
tra et al., 2013), we asked whether the activity or expression 
of these Cbl proteins was affected in IFT20-depleted cells. 
First, we found that Cbl-b protein levels are up-regulated upon 
serum starvation–induced ciliogenesis in NIH3T3 and retinal 
pigmented epithelial (RPE) 1 cells, whereas the level of c-Cbl 
was unaffected by serum depletion (Fig. 3 a), suggesting that 
Cbl-b may carry out specific functions associated with growth 
arrest or ciliary signaling events or both. Time-course exper-
iments in NIH3T3shIFT20 cells revealed that c-Cbl and Cbl-b 
levels declined concomitant with the reduction in IFT20 lev-
els. The levels of c-Cbl and Cbl-b were significantly reduced 
after 2 d of Dox treatment and were barely detectable after 6 d 
(Fig. 3 b). Likewise, reduced levels of c-Cbl were also detected 
in human embryonic kidney (HEK) 239T cells transfected with 
shRNA against IFT20 (Fig. S2 b). In contrast, protein levels of 
those ubiquitin ligases were largely unaffected in WT NIH3T3 
cells subjected to siRNA-mediated depletion of IFT88 (Fig. S2 
c) as well as in knockout mouse embryonic fibroblasts lack-
ing IFT172 or the kinesin II motor subunit Kif3a (Fig. S2 d), 
both required for formation of primary cilia (Taschner and 
Lorentzen, 2016). Therefore, the effect of IFT20 depletion on 
Cbl protein stability seems not to be solely a consequence of 
ciliary loss. Further, the reduction in c-Cbl and Cbl-b levels in 
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Figure 1. Conditional gene silencing of IFT20 is associated with defects in termination of PDG FRα signaling. (a) Experimental setup to verify IFT20 silencing 
efficiency in NIH3T3shIFT20 cells upon treatment with Dox for given times. All cells were grown for 6 d. Asterisks indicate day of Dox addition. (b) WB analy-
sis showing IFT20 expression in NIH3T3shIFT20 cells during 0–6 d of Dox treatment using the experimental setup outlined in panel a. (c–e) IFM images of 
growth-arrested NIH3T3shIFT20 cells treated without (− Dox) or with Dox (+ Dox) for 6 d, showing cellular localization of IFT20. Primary cilia (arrows) were 
labeled with anti–acetylated α-tubulin (Ac-tub) or anti-detyrosinated α-tubulin (Glu-tub), and the ciliary base/centrosome was labeled with anti–p150glued (as-
terisks). Nuclei (nu) were visualized with DIC microscopy or DAPI staining. Anti–Giantin was used to label the Golgi complex (dashed line). (f) Percentage 
of ciliated NIH3T3shIFT20 cells after Dox treatment, as indicated. Error bars represent means ± SEM (n = 3). (g) WB analysis of phosphorylation of PDG FRα 
(p-PDG FRα), AKT (p-AKT), and ERK1/2 (p-ERK1/2) upon stimulation with PDGF-AA for indicated times in growth-arrested NIH3T3shIFT20 cells treated with or 
without Dox treatment for 6 d. (h) Quantification of protein phosphorylations shown in panel g. Error bars represent means ± SEM (n = 3). (i) WB analysis 
of c-Cbl and Cbl-b levels in growth-arrested NIH3T3shIFT20 cells as well as in cells stably expressing siRNA-resistant, GFP-tagged IFT20 (NIH3T3shIFT20-Res) 
after Dox treatment for 6 d. (j) IFM analysis of NIH3T3shIFT20-Res cells with or without Dox treatment for 6 d. Cells were stained with antibodies against GFP 
and IFT20, and cell nuclei were visualized with DAPI staining. Primary cilia (arrows) were labeled with anti–Glu-Tub and anti–Ac-tub and are shown as 
shifted overlays. Quantification of ciliated NIH3T3shIFT20-Res cells; error bars represent means ± SEM (n = 3). (k) WB analysis of phosphorylation of PDG FRα 
(p-PDG FRα) and AKT (p-AKT) upon stimulation with 50 ng/ml PDGF-AA for indicated times in growth-arrested NIH3T3shIFT20 versus NIH3T3shIFT20-Res cells, 
both treated with Dox for 6 d. (l) Quantification of protein phosphorylations shown in panel k. Error bars represent means ± SEM (n = 3).
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Dox-treated NIH3T3shIFT20 cells was a specific consequence of 
the IFT20 depletion because Cbl protein levels could be signifi-
cantly restored in Dox-treated NIH3T3shIFT20-Res cells (Fig. 1 i), 
and no decrease in their levels could be observed in Dox-treated 
WT NIH3T3 cells (Fig. S2 e). Moreover, NIH3T3shIFT20 cells 
that had been serum starved before IFT20 depletion showed a 
similar reduction in c-Cbl levels after 6 d of Dox treatment (Fig. 
S2, f and g), indicating that the observed decline in c-Cbl pro-
tein levels was not secondary to cell cycle defects. In addition, 
knockdown of c-Cbl by siRNA in WT NIH3T3 and RPE-1 cells 
reduced IFT20 protein levels (Fig. 3 c), without decreasing the 
level of Ift20 mRNA (Fig. S2 h), supporting the conclusion of 
a functional and biochemical interdependence between IFT20 
and c-Cbl on the protein level.
Assessment of mRNA levels by quantitative, real-time PCR 
revealed no significant difference between c-Cbl and Cbl-b mRNA 
levels from untreated versus Dox-treated (for 6 d) NIH3T3shIFT20 
cells (Fig. 3 d), highlighting that reduced amounts of Cbl proteins 
in IFT20-depleted cells manifest at a posttranscriptional level. 
Because c-Cbl can modulate its own turnover by a negative feed-
back mechanism that involves autoubiquitination (Ryan et al., 
2006), we studied whether cellular loss of IFT20 triggers auto- 
ubiquitination and proteasomal degradation of c-Cbl. Blocking 
proteasomal degradation by the addition of MG-132 substantially 
restored the amount of c-Cbl in Dox-treated NIH3T3shIFT20 cells, 
whereas lysosomal inhibition by NH4Cl showed no obvious effect 
(Fig. 3 e). Supportively, IFT20 depletion caused excessive c-Cbl 
polyubiquitination, evident by the increase in low-mobility ubiq-
uitin species in c-Cbl immunoprecipitates, which was paralleled 
by a concomitant reduction in c-Cbl protein (Fig. 3 f). To investi-
gate whether c-Cbl degradation was a result of autoubiquitination, 
we generated two NIH3T3shIFT20 cell lines that stably expressed 
human FLAG–tagged WT c-Cbl (NIH3T3shIFT20,FLAG–c-Cbl-WT) or 
RING-finger mutant c-Cbl (NIH3T3shIFT20,FLAG–c-Cbl,*RING). When 
IFT20 was depleted, FLAG-tagged, WT c-Cbl was depleted to an 
extent similar to the corresponding, endogenous c-Cbl protein, 
whereas the stability of RING-mutated c-Cbl remained unaf-
fected (Fig. 3 g), demonstrating that the process leading to c-Cbl 
degradation requires its innate enzyme activity. Further, because 
the ability of Cbl proteins to form dimers is crucial to establish a 
negative-feedback response to activated PDG FRα signaling (Ko-
zlov et al., 2007; Peschard et al., 2007), we evaluated whether 
c-Cbl could dimerize in the absence of IFT20. Therefore, we 
transiently expressed GFP-tagged RING-mutant c-Cbl (GFP-c-
Cbl*RING) in NIH3T3shIFT20,FLAG–c-Cbl*RING cells and monitored the 
amount of GFP-tagged c-Cbl*RING in FLAG immunoprecipitates 
under untreated and Dox-treated conditions. Thereby, a change 
in the amount of GFP-tagged c-Cbl*RING could be assessed, inde-
pendent of autoubiquitination and degradation of the protein. We 
found that c-Cbl homodimers were unstable in IFT20-deficient 
cells, which was evident by the reduction in coprecipitated, GFP-
tagged c-Cbl*RING (Fig. 3 h), indicating that IFT20 is also required 
to promote formation of stable c-Cbl dimers.
To confirm those findings, we tested whether defects 
in the feedback inhibition of PDG FRα signaling in IFT20- 
depleted cells could be phenocopied by depletion of Cbl pro-
teins. We performed siRNA knockdown experiments in WT 
NIH3T3 cells and examined activation of PDG FRα and AKT 
upon PDGF-AA stimulation in serum-starved cells. Interestingly, 
a significant increase and prolongation of PDG FRα signaling was 
only detected in cells depleted for both c-Cbl and Cbl-b (Fig. 3, 
i and j), which is consistent with our findings in IFT20-deficient 
cells (Fig. 1, g–i). To our knowledge, this result demonstrates for 
the first time that removal of both Cbl ubiquitin ligases is required 
for efficient down-regulation of PDG FRα signaling.
IFT20 interacts with Cbl proteins, and 
c-Cbl is targeted to the cilium upon  
PDGF-AA stimulation
Because IFT20 is required for stability and function of c-Cbl 
and Cbl-b, we then asked whether those proteins interact physi-
cally with IFT20. We initially evaluated such an interaction with 
Figure 2. Conditional gene silencing of IFT20 in-
hibits ubiquitination and internalization of PDG FRα. 
(a) PDG FRα ubiquitination upon stimulation with 
PDGF-AA for 10 min in growth-arrested NIH3T3shIFT20 
cells cultured with or without Dox for 6 d before li-
gand addition. IP with anti–PDG FRα was performed 
on lysates of cells not transfected (left) or transfected 
with a construct expressing Myc-tagged ubiqui-
tin (right), and IPs were analyzed by WB using 
antibodies against mono- and polyubiquitin or 
Myc, respectively. The experiments were repeated 
three times, and results from one representative 
experiment are shown. (b) WB analysis of surface- 
biotinylated PDG FRα upon stimulation with PDGF-AA 
for indicated times in growth-arrested NIH3T3shIFT20 
cells treated with or without Dox for 6 d.  Cell 
surface proteins were labeled with biotin before 
(internalized) or after (surface) stimulation with 
PDGF-AA, followed by IP with streptavidin beads. 
To detect internalized PDG FRα specifically, extra-
cellular biotin was removed after stimulation with 
an alkaline glutathione solution. (c) Quantification 
of protein-band intensity for experiment shown in 
panel b. Error bars represent means ± SEM (n = 3).
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a FLAG–IFT20 IP assay in HEK293T-cell extracts and mass 
spectrometric analysis of coprecipitated immunocomplexes. We 
found c-Cbl to coprecipitate with FLAG–IFT20 (Fig. S3 a and 
Table S1), and that interaction was confirmed by IP of FLAG-
tagged c-Cbl (FLAG–c-CblWT) when GFP-tagged IFT20 was co-
precipitated (Fig. 4 a). Supportively, IP of endogenous proteins 
demonstrated binding of c-Cbl to IFT20 and vice versa (Fig. 4, 
b and c), suggesting that those proteins interact physically. 
Because heterodimerization of c-Cbl and Cbl-b relies on their 
C-terminal ubiquitin-associated/leucine zipper domains (Liu et 
al., 2003; Rorsman et al., 2016), we further asked whether Cbl-b 
might participate in an IFT20–c-Cbl complex. Initially, we found 
that Cbl-b was immunoprecipitated with FLAG–c-CblWT as well 
as with a defective form of ubiquitin ligase carrying the mutation 
p.C381A in the RING-finger domain of c-Cbl (Waterman et al., 
1999; FLAG–c-Cbl*RING; Fig. 4 d), indicating that the interaction 
between c-Cbl and Cbl-b was independent of ubiquitin ligase 
activity. Indeed, reciprocal IFT20 pulldown of cell extracts from 
FLAG–c-Cbl expressing cells coprecipitated both endogenous 
Cbl-b and FLAG–c-Cbl. Interestingly, although the protein lev-
els of IFT20 in those cells remained unchanged, IFT20 appeared 
to bind more avidly to RING-mutated FLAG–c-Cbl and Cbl-b 
than it did with WT FLAG–c-Cbl (Fig. 4 e). Despite those find-
ings, size-exclusion chromatography of extracts from HEK293T 
cells revealed only a minor overlap between the elution profile of 
IFT20 and those of c-Cbl and Cbl-b (Fig. S3 b), suggesting that 
Figure 3. Cbl family E3 ubiquitin ligases are degraded in cells with reduced IFT20, leading to defects in termination of PDG FRα signaling. (a) WB analysis 
showing expression levels of c-Cbl and Cbl-b proteins in cycling (+ serum) and growth-arrested (− serum) NIH3T3 and RPE-1 cells. CDK1 marks cycling 
cells. (b) WB analysis of c-Cbl and Cbl-b in growth-arrested NIH3T3shIFT20 cells upon addition of Dox for 1–6 d. All cells were grown for 6 d, including 
24 h of serum depletion before analysis. An unspecific band stained by the IFT20 antibody is labeled with an asterisk. (c) WB analysis of IFT20 in growth- 
arrested NIH3T3 and RPE-1 cells subjected to mock or siRNA(siR)-mediated silencing of c-Cbl. (d) Quantitative, real-time PCR analysis of relative Ift20, 
c-Cbl, and Cbl-b mRNA transcript levels in NIH3T3shIFT20 upon 6 d of Dox treatment, including 24 h of serum depletion. Error bars represent means ± 
SEM (n = 3). (e) WB analysis of c-Cbl and Cbl-b in cycling NIH3T3shIFT20 cells upon Dox treatment for 3 d in combination with lysosomal (NH4Cl) or 
proteasomal (MG-132) inhibitors for 24 h or 10 h, respectively. (f) IP of endogenous c-Cbl in NIH3T3shIFT20 cells with or without Dox for 3 d, followed by 
WB analysis with antibodies against mono- and polyubiquitin. (g) WB analysis of growth-arrested NIH3T3shIFT20 cells stably expressing FLAG–tagged WT 
or RING-mutant c-Cbl (NIH3T3shIFT20,FLAG–c-Cbl,WT and NIH3T3shIFT20,FLAG–c-Cbl*RING, respectively) upon 6 d of Dox treatment. (h) FLAG IP of protein lysates from 
NIH3T3shIFT20,FLAG–c-Cbl*RING cells transiently expressing GFP-tagged c-Cbl RING mutant (GFP-c-Cbl*RING) after treatment with Dox for 4 d. Experiments pre-
sented in panels a–c and e–h were repeated at least three times, and results from representative experiments are shown. (i) WB analysis of phosphorylation 
of PDG FRα (p-PDG FRα) and AKT (p-AKT) upon stimulation with 50 ng/ml PDGF-AA for indicated times in NIH3T3 cells subjected to siRNA (siR)-mediated 
silencing of c-Cbl, Cbl-b, or both for 72 h, including serum depletion for the last 24 h before stimulation to induce growth arrest. (j) Quantification of protein 
phosphorylations shown in panel i. Error bars represent means ± SEM (n = 3).
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only a fraction of the cellular IFT20 was complexed with the Cbl 
proteins. This is not surprising given that IFT20 is an integral 
component of the IFT-B subcomplex (Cole et al., 1998; Taschner 
et al., 2016). Collectively, these results suggest that only a por-
tion of cellular IFT20 interacts physically with both c-Cbl and 
Cbl-b and that the interaction between IFT20 and Cbl-b may, in 
part, be mediated through binding to c-Cbl, although that con-
jecture requires further examination.
To investigate whether a link exists between IFT20 inter-
action and the function of Cbl proteins in the primary cilium, 
we monitored the localization of c-Cbl in the presence and in 
the absence of PDGF-AA in ciliated WT NIH3T3 and inner 
medullary collecting duct 3 (IMCD3) cells by IFM analysis. 
Initially, GFP-tagged c-Cbl was shown to localize predomi-
nantly at the base and the proximal part of the primary cil-
ium as well as in the Golgi complex in unstimulated NIH3T3 
cells (Fig. 4, f–i). After 10 min of PDGF-AA stimulation, en-
dogenous c-Cbl was enriched in the primary cilium, whereas 
Golgi localization was largely unaffected (Fig. 4, j–l). Based 
on those observations, we suggest that the Golgi complex 
and the ciliary-base region are potential compartments for in-
teraction between IFT20 and Cbl proteins and that the Cbl 
proteins are recruited to the cilium to initiate feedback inhibi-
tion of activated PDG FRα.
Figure 4. IFT20 interacts with Cbl-b and c-Cbl, which is targeted to the cilium in PDGF-AA–stimulated cells. (a) Validation of the IFT20-c-Cbl interaction. 
HEK293T cells coexpressing GFP-IFT20 with either FLAG–tagged WT c-Cbl (FLAG–c-CblWT) or empty FLAG vector were subjected to FLAG IP, followed by 
WB analysis. (b and c) Reciprocal IPs of endogenous IFT20 or c-Cbl from HEK293T cells. (d) FLAG IP of HEK293T cell extracts expressing FLAG–c-CblWT 
or FLAG–tagged RING mutant (p.C381A) c-Cbl (FLAG–c-Cbl*RING). (e) IFT20 IP of HEK293T cell extracts expressing FLAG–c-CblWT or FLAG–c-Cbl*RING, fol-
lowed by WB analysis. (f) IFM of WT NIH3T3 cells coexpressing GFP-tagged c-Cbl and FLAG–tagged IFT20. The dashed line indicates the Golgi complex, 
the arrow shows the primary cilium, and the asterisks identify the ciliary base. The nucleus was visualized with DAPI. (g) IFM of WT NIH3T3 cells expressing 
GFP-tagged c-Cbl. The primary cilium was marked with anti–ARL13B (arrow). The dashed line indicates the Golgi complex, and asterisk indicates the ciliary 
base. The nucleus was visualized with DAPI. The outline of the cells in panels f and g is highlighted with a dashed line. (h and i) IFM of WT NIH3T3 cells 
expressing either GFP-tagged c-Cbl (h) or stained with anti–c-Cbl (i). The Golgi complex (dashed line) was labeled with anti–GM130, and the nucleus was 
visualized with DAPI. (j) Localization of c-Cbl to the primary cilium in WT NIH3T3 cells, labeled with anti–Ac-tub (arrow), in WT NIH3T3 cells before and 
after stimulation with PDGF-AA. The asterisk marks the ciliary base. The nucleus was visualized with DAPI. (k) Localization of c-Cbl to the primary cilium 
in WT NIH3T3 cells and labeled with anti–ARL13B (arrow) in IMCD3 cells before and after stimulation with PDGF-AA. The asterisk marks the ciliary base. 
The nucleus was visualized with DAPI. (l) Quantification of relative levels of c-Cbl in the primary cilium shown in panel k. Fluorescence was normalized to 
background levels. For each of the three experiments, >15 cells were quantified. Error bars represent means ± SEM (n = 3).
IFT20 controls Cbl-mediated inhibition of PDG Frα • Schmid et al. 157
PDG FRα mislocalizes to the plasma 
membrane in cells with reduced IFT20  
and Cbl proteins
Because PDG FRα is labeled at the cell surface (Fig. 2 b) and is 
capable of being activated by PDGF-AA in IFT20-depleted cells 
(Fig. 1, g and h), we inferred that the receptor under those cir-
cumstances was aberrantly localized to the cell surface outside 
the primary cilium. To confirm that hypothesis, we generated 
NIH3T3shIFT20 cells that stably expressed GFP-tagged PDG FRα 
(NIH3T3shIFT20,GFP–PDG FRα; Fig. 5, a and b) and subjected those 
cells to Dox treatment. In growth-arrested, untreated cells, the 
GFP-tagged receptor localized to the primary cilium, in the 
Golgi, and at the perinuclear region surrounding the Golgi com-
plex (Fig. 5, a and c), as previously described for RPE-1 cells 
(Nielsen et al., 2015). In contrast, GFP–PDG FRα localization 
was more dispersed throughout the cytosol in IFT20-deficient 
cells, with part of the receptor population localizing at the 
plasma membrane and often to patches at that site (Fig.  5, a 
and e). Similar results were obtained for endogenous PDG FRα 
in NIH3T3shIFT20 cells (Fig. 5 d), whereas in WT NIH3T3 cells 
treated with Dox, the receptor was undetectable at the plasma 
membrane (Fig. S3 c). Quantification of GFP–PDG FRα flu-
orescence intensity, in a 5-µm region spanning from the cell 
surface into the cell, revealed significantly more of the receptor 
close to the cell surface (Fig. 5, e and f). Similarly, GFP-tagged 
PDG FRα was also enriched at the lamellipodium of migrating 
cells deficient for IFT20 (Fig. 5 g), indicating that localization 
of the receptor to the plasma membrane in the absence of IFT20 
is linked to cell polarity. Because IFT20 stabilizes c-Cbl and 
Cbl-b to modulate PDG FRα signaling, we further investigated 
the localization of the receptor in NIH3T3shIFT20,GFP–PDG FRα cells 
subjected to siRNA-mediated knockdown of both Cbl proteins. 
Under those conditions, GFP-tagged PDG FRα was similarly 
localized toward the plasma membrane (Fig. 5 h) and promi-
nently confined in puncta along extensive cellular protrusions 
(Fig. S3 d). These results underscore the functional relationship 
between IFT20 and Cbl proteins in receptor sorting and modu-
lation of PDG FRα signaling.
Our results support the conclusion that defects in IFT pro-
teins and ciliary trafficking affect PDG FRα signaling by different 
mechanisms. In contrast to IFT20 depletion, fibroblasts lacking 
IFT88 and IFT172 have reduced PDG FRα expression, and the 
receptor cannot be activated by stimulation with PDGF-AA 
(Schneider et al., 2005; Umberger and Caspary, 2015). There 
are several possibilities to explain those differences. Based on 
our findings, one model would be that IFT20 in collaboration 
with c-Cbl and Cbl-b ensures targeting of PDG FRα from the 
Golgi complex to the cilium and, at the same time, impedes 
localization in the plasma membrane. Whether trafficking from 
the Golgi complex to the cilium follows a direct pathway or is 
regulated via recycling endosomes from the plasma membrane, 
as shown for polycystin-2 (Monis et al., 2017), remains un-
known. Upon PDGF-AA binding to the receptor, Cbl proteins 
accumulate in the primary cilium to coordinate the processes 
of receptor ubiquitination and internalization for balanced 
feedback inhibition of PDG FRα signaling (Fig. 5 i). However, 
further investigations are required to understand whether that 
accumulation is caused by changes in the rate of ciliary entry 
or the rate of ciliary exit of the proteins and whether ciliary 
accumulation is regulated by interaction with IFT20 or by other 
proteins in the cilium proper. In particular, IFT20 appears to be 
especially important for complex integrity because depletion of 
IFT20, but not IFT88 or IFT172, results in degradation of both 
Cbl proteins, whereas depletion of one of the Cbl proteins alone 
seems to have little effect on the stability of the other paralog. 
In support of that understanding, only codepletion of c-Cbl and 
Cbl-b caused overactivation of PDG FRα signaling and recep-
tor localization to the plasma membrane, thus phenocopying 
IFT20 knockdown and underscoring the importance of IFT20 
for maintenance of the stability and function of Cbl proteins. 
Interestingly, fibroblasts deficient in the IFT-A subcomplex pro-
tein IFT122, which display swollen or bulgy cilia because of 
defective, retrograde IFT (Ocbina et al., 2011), show normal 
levels of PDG FRα, which can be activated by short term stimu-
lation with PDGF-AA (Umberger and Caspary, 2015), indicat-
ing that the receptor in those cells is targeted to the cilium for 
activation. However, because IFT122 has been shown to regu-
late the balanced output of cellular signaling through the coor-
dinated trafficking of signaling constituents out of the cilium, 
such as in Hedgehog signaling (Qin et al., 2011), we surmise 
that feedback inhibition PDG FRα signaling in IFT122-deficient 
fibroblasts could be affected in IFT122-deficient cells, although 
that is speculative at this point.
Finally, it will be important to investigate whether the 
interaction between IFT20 and Cbl proteins also occurs in 
cell types other than fibroblasts and whether such interplay is 
disrupted in disease. IFT20 governs clustering of a functional 
TCR/CD3 complex containing LAT at the immune synapse in 
T cells (Finetti et al., 2009, 2014; Vivar et al., 2016), and Cbl 
proteins also have important roles in TCR turnover, and muta-
tions in c-Cbl cause leukemia and autoimmune diseases (Li-
yasova et al., 2015). In a recent study, osteoblasts derived from 
IFT20 knockout mice embryos were shown to display mildly 
reduced AKT phosphorylation in response to short term stimu-
lation with PDGF-AA (Noda et al., 2016). Although that study 
did not address the role of IFT20 in modulation of feedback 
inhibition of PDG FRα signaling during long-term stimulation 
with PDGF-AA, there might be cell type–specific differences or 
adaptations because of the long-lasting lack of IFT20 and Cbl 
proteins in mutant osteoblasts. Thus, investigating Cbl proteins 
in that context would be very informative toward elucidating 
how cells compensate to survive those deleterious effects and 
become tumorigenic. Indeed, aberrant PDG FRα signaling has 
been linked to a broad range of human pathologies, such as gas-
trointestinal stromal tumors (Andrae et al., 2008; Corless et al., 
2011) and glioblastoma (Heldin and Lennartsson, 2013), and 
defects in Cbl proteins account for the pathogenesis of leukemia 
and autoimmune diseases (Liyasova et al., 2015). Likewise, de-
fects in the function of primary cilia have been associated with 
tumorigenesis and cancer (Seeger-Nukpezah et al., 2013).
Materials and methods
Reagents
The following antibodies were used: R&D Systems: goat anti-PDG FRα 
(AF1062); Proteintech: rabbit anti–human IFT20 (13615–1-AP), rab-
bit anti-IFT88 (13967-1-AP); Sigma-Aldrich: mouse anti–α-tubulin 
(T5168), mouse anti–acetylated α-tubulin (T6793), mouse anti-FLAG 
(M2; F1802), rabbit anti-FLAG (F7425); BD Biosciences: mouse anti- 
CDK1 (610038), mouse anti-p150Glued (610474), mouse anti-GM130 
(610823); Enzo life Sciences: mouse anti-giantin (ALX-804-600-C100), 
mouse anti–mono- and polyubiquitin (FK2; BML-PW8810); Abcam: 
mouse anti–c-Cbl (Ab119954), rabbit anti–c-Cbl (Ab32027), mouse 
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anti-GFP (Ab1218), chicken anti-GFP (Ab13970), rabbit anti–dety-
rosinated α-tubulin (Ab48389), rabbit anti-PDG FRα (Ab134123); 
Cell Signaling Technology: rabbit anti-Myc (2278), rabbit anti-GAP 
DH (2118), rabbit anti–Cbl-b (9498), rabbit anti-Akt (9272), rabbit 
anti–phosphorylated Akt (Ser473; 4060), rabbit anti-Erk1/2 (9102), 
rabbit anti–phosphorylated Erk1/2 (Thr202/Tyr204; 9101), rabbit 
anti–phosphorylated Rb (9308); Santa Cruz Biotechnology: rabbit 
anti–c-Cblsc-170), mouse anti–c-Cbl (sc-1651), mouse anti-GFP (sc-
9996), rabbit anti-GFP (sc-8334), rabbit anti–phosphorylated PDG FRα 
(Tyr754; sc-12911R). For RNAi-mediated gene-silencing experiments, 
custom siRNAs were purchased from Eurofins Genomics. The siRNA 
sequences 5′-UAA UGU AUU GGA AGG CAUA-3′ or 5′-CCA ACG 
Figure 5. PDG FRα localizes at the plasma membrane in IFT20-depleted cells. In all experiments, cells were incubated with or without Dox for 6 d, including 
serum depletion for 24 h before analysis. (a) IFM of NIH3T3shIFT20 cells expressing GFP-tagged PDG FRα (NIH3T3shIFT20,GFP-PDG FRα) stained with anti–IFT20 
and anti–GM130 to label the Golgi complex (dashed line). Nuclei (Nu) were visualized with DAPI. Arrows indicate receptor localization at the plasma 
membrane. The outline of the cells is highlighted by a dashed line. (b) WB analysis of PDG FRα and GFP-PDG FRα in NIH3T3shIFT20 and NIH3T3shIFT20,GFP-PDG FRα 
with or without Dox. GAP DH was used as the loading control. (c) IFM showing localization of GFP–PDG FRα to the primary cilium (arrow) labeled with 
anti–Ac-tub in the absence of Dox. (d) IFM of localization of endogenous PDG FRα in NIH3T3shIFT20 cells with or without Dox. Nuclei (Nu) were visualized 
with DIC microscopy. Arrows indicate receptor localization at the plasma membrane. (e and f) Relative levels of GFP fluorescence at the cell surface in 
NIH3T3shIFT20,GFP-PDG FRα cells, corresponding to a 5-µm area starting from the cell surface into the inside of the cell (e). GFP fluorescence was normalized to 
background levels. For each of 3 experiment, >15 cells were quantified. Error bars represent SEM (n = 3; f). (g) IFM analysis of GFP-PDG FRα localization 
in migrating NIH3T3shIFT20,GFP-PDG FRα cells with or without Dox. Arrows indicate localization of receptors to the leading-edge membrane of the lamellipodia 
(lam.) in cells treated with Dox. (h) IFM analysis of GFP-PDG FRα localization in NIH3T3shIFT20,GFP-PDG FRα cells subjected to siRNA-mediated silencing of both 
c-Cbl and Cbl-b. GM130 labels the Golgi complex. Arrows indicate localization of receptors at the plasma membrane (h) and to cellular protrusions in cells 
treated with Dox. Nuclei were visualized with DAPI. (i) Proposed model for the role of IFT20 in modulating PDG FRα signaling. IFT20 interacts with c-Cbl 
and Cbl-b to orchestrate the ubiquitination and internalization of ligand-activated PDG FRα for signaling termination. In the presence of IFT20 (left), PDG FRα 
is activated with proper feedback inhibition at the primary cilium, but in IFT20-depleted cells with defective ciliogenesis (right), PDG FRα mislocalizes to the 
plasma membrane from where the receptor is overactivated because of autoubiquitination-induced degradation of c-Cbl and Cbl-b.
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ACC UGG AGA UUAA-3′ were used for mock or for gene silencing 
of mouse IFT88, respectively. Sequences of other siRNAs used in this 
manuscript have been described elsewhere: siRNA against human (Sel-
bach and Mann, 2006) and mouse (Mitra et al., 2004) c-Cbl, and siRNA 
against mouse Cbl-b (Hinterleitner et al., 2012). Cells were transfected 
at a concentration of 300 nM of total siRNA and incubated for 72 h 
to induce an efficient mRNA silencing. Recombinant PDGF-AA (at 
50 ng/ml) was purchased from R&D Systems. Cells were treated with 
the following chemicals: MG-132 (10 µM for 10 h; Selleck Chemicals), 
NH4Cl (10 mM for 24 h; Sigma-Aldrich), and Dox (0.5 µg/ml for 3, 
4, or 6 d; Sigma-Aldrich). If not otherwise stated, concentration and 
incubation times indicated in brackets have been applied.
Plasmid constructs
For plasmid constructs inducibly expressing shRNA against human 
and mouse IFT20, DNA sequences previously described (Follit et al., 
2006) were cloned into pSuperior (Oligoengine), following the manu-
facturer’s protocol. For the construct expressing GFP-tagged, siRNA- 
resistant IFT20 (pJAF2.13-Res), pJAF2.13 (Follit et al., 2006; pro-
vided by G.  Pazour, University of Massachusetts Medical School, 
Worcester, MA) was mutated using Agilent’s QuickChange II site- 
directed mutagenesis kit and mutant primers. A construct expressing 
C-terminal–GFP-tagged PDG FRα was used for stable expression in 
NIH3T3shIFT20 cells and was generated in two steps, by first, transferring 
the GFP-coding sequence from pEGFP-N1 (Clontech) into pcDNA5/
FRT (Life Technologies) using HindIII and NotI restriction sites to get 
pcDNA5/FRT-GFP. In the second step, PDG FRα-coding sequence was 
cloned from PDG FRα WT-GFP into pcDNA5/FRT-GFP using HindIII 
and KpnI. Cloning of PDG FRα WT-GFP has been described previously 
(Nielsen et al., 2015). Plasmid expressing human c-Cbl was purchased 
from Origene (RC214069). To generate c-Cbl *RING FLAG, the 
ubiquitin ligase–inactivating mutation p.C381A (Joazeiro et al., 1999; 
Waterman et al., 1999) was introduced by standard PCR using mutant 
primers and the same flanking primers as used to generate c-Cbl WT 
FLAG. Truncated versions of c-Cbl were produced by standard PCR on 
c-Cbl WT FLAG using specific, reverse primers that bind to C-terminal 
ends of selected protein-binding domains of c-Cbl and by using the 
same forward primer. The construct expressing the GFP-tagged c-Cbl 
RING mutant (c-Cbl *RING GFP) was obtained by cloning the c-Cbl 
coding sequence from c-Cbl *RING FLAG into pEGFP-N1. Plasmid 
expressing Myc-tagged ubiquitin was a gift from J. Bartek at the Dan-
ish Cancer Society (Copenhagen, Denmark). Correct sequences for all 
constructs were verified by Sanger sequencing using the sequencing 
service from Eurofins Genomics.
Mammalian cell culture, transfection, and generation of stable  
cell lines
HEK293, NIH3T3, IMCD3, and RPE-1 cells were grown in DMEM 
(Life Technologies), supplied with 10% FBS and 1% penicillin/strep-
tomycin (Gibco). If not otherwise stated, ciliogenesis was induced by 
serum depletion for 24 h. For transfection with siRNA or plasmid DNA 
constructs, DharmaFECT Duo (Dharmacon) or FuGENE 6 (Promega) 
were used, respectively, by following manufacturers’ protocols. To 
generate the NIH3T3shIFT20 cell line for Dox-inducible depletion of 
IFT20, pSuperior (Oligoengine) containing shRNA targeting mouse 
IFT20 was cotransfected with pcDNA6/TR (Life Technologies) fol-
lowing the manufacturer’s instructions. Cells stably expressing both 
constructs were selected with 5 µg/ml puromycin (Gibco) and 10 µg/
ml blasticidin (Life Technologies). Cell lines NIH3T3shIFT20,shIFT20-Res, 
NIH3T3shIFT20,GFP-PDG FRα, NIH3T3shIFT20,FLAG–c-Cbl,WT, and NIH3T3shIFT20,-
FLAG–c-Cbl*RING were generated by transfection of NIH3T3shIFT20 cells 
with pJAF2.13-Res, PDG FRα WT-GFP, FLAG–c-CblWT, or FLAG–c-
Cbl*RING, respectively. In addition to selection with puromycin and 
blasticidin, NIH3T3shIFT20,GFP-PDG FRα, NIH3T3shIFT20,FLAG–c-Cbl,WT, 
and NIH3T3shIFT20,FLAG–c-Cbl*RING cell lines were grown in 30 µg/ml Hy-
gromycin B (Life Technologies), whereas NIH3T3shIFT20,shIFT20-Res was 
grown in 800 µg/ml G418 (Sigma-Aldrich).
Immunofluorescence, microscopic analysis, and quantification of  
GFP fluorescence
Cells were grown on glass coverslips and fixed in either 4% PFA or 
100% methanol for 15 min at RT or 10 min at −20°C, respectively. 
For PFA fixed cells, cell membranes were permeabilized by incuba-
tion in 1× PBS, 1% BSA, and 0.2% Triton X-100 for 12 min at RT. 
Thereafter, cells were incubated in 1× PBS and 2% BSA for 30 min 
at RT to block unspecific binding of antibodies, followed by overnight 
incubation with primary antibodies at 4°C. After PBS washing steps, 
cells were incubated in corresponding Alexa Fluor–conjugated second-
ary antibodies (Invitrogen) for 45 min at RT. Cell nuclei were labeled 
by DAPI staining or detected through differential interference contrast 
(DIC) microscopy. Coverslips were mounted in 1× PBS, 90% glycerol, 
and 2% N-propyl-gallate on glass slides and sealed with nail polish. 
Images were captured on a fully motorized BX63 upright microscope 
(Olympus) with a DP72 color, 12.8-megapixel, 4,140 × 3,096–reso-
lution camera, and DIC. For quantification of receptor localization, 
the mean fluorescence value of GFP-PDG FRα at a region compris-
ing a 5-µm area, starting from the cell surface into the inside of the 
cell, was set relative to the fluorescence value of the entire cell. For 
quantification of c-Cbl fluorescence in the primary cilium, values in 
the cilium region were set relative to the fluorescence values in back-
ground areas of the cytosol.
Quantitative, real-time PCR
Total RNA was extracted from cells with Nucleospin RNA II kit 
(Macherey-Nagel) following the manufacturer’s protocol. 1 µg of 
total RNA was reverse-transcribed into cDNA using SuperScript III 
reverse transcription (Life Technologies). The quantitative, real-time 
PCR reactions were performed on a 7500 Fast Real-Time PCR system 
from Applied Biosystems with Lightcycler Fast Start DNA Master plus 
SYBR Green I (Roche). Transcript levels of genes of interest were nor-
malized to transcript levels of housekeeping genes GAP DH, HRP, and 
PSMD4, and means were obtained.
Cell lysis, IP, SDS PAGE, and WB analysis
Total protein was extracted by cell lysis in SDS (10  mM Tris-HCl 
and 1% SDS), EBC buffer (140 mM NaCl, 50 mM Tris-HCl, 1 mM 
Na3VO4, 5 mM EDTA, and 0.5% NP-40), or CHA PS buffer (20 mM 
Tris, 20 mM NaCl, 1 mM EDTA, 5 mM EGTA, 1 mM dithiothreitol, 
and 0.1% CHA PS, pH 7.4) plus protease inhibitor cocktail (Roche), 
followed by clearing of cell lysates through centrifugation at 20.000 g 
for 30 min. For IP assays, anti-FLAG (M2) antibody–conjugated aga-
rose beads or protein A– or G–conjugated sepharose beads (Sigma- 
Aldrich) in combination with their corresponding antibodies were used, 
following the manufacturer’s instructions. Proteins were eluted from 
five-time prewashed immunocomplexes using 2× LDS sample buffer 
(IPs for ubiquitination and dimerization experiments; Life Technolo-
gies), 0.2 mM glycine, pH 2.5 (IPs for protein interaction studies), or 3× 
FLAG peptide (IP for mass spectrometry [MS]). SDS-PAGE and WB 
analysis with corresponding antibodies was performed as previously 
described (Schrøder et al., 2011; Nielsen et al., 2015). Membranes 
were incubated with secondary antibodies conjugated with either al-
kaline phosphatase or HRP and developed with BCIP/NBT (Kem- 
En-Tec Diagnostics) and ECL Western Blotting Detection Reagents 
(GE Healthcare Life Sciences), respectively. Band intensities from blots 
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obtained with colorimetric substrate (scanned blots) and chemilumines-
cence were estimated from arbitrary densitometric values obtained with 
UN-SCAN-IT version 5.1 software (Silk Scientific, Inc.). Blots were 
further processed for publication with Photoshop version CS6 (Adobe) 
using the Level function for contrast adjustment. Processing was ap-
plied equally across the entire blot and equally to controls. 
Size-exclusion chromatography
Native protein complexes from HEK293T cells were run by HPLC 
on an NaPO4-buffered Superose 6 column 10/300 GL (GE Health-
care Life Sciences), and collected fractions were concentrated 
by vacuum centrifugation.
MS
SDS-PAGE–resolved, 4–12%-gradient gels were silver-stained with 
SilverQuest (Life Technologies), and appropriate bands were cut and 
subjected to in-gel digestion, followed by liquid chromatography–MS 
with a Q Exactive HF system (Thermo Fisher Scientific). Result-
ing peptides were identified by protein-sequence database searches 
using MaxQuant software.
Biotinylation assays
Cell surface proteins were labeled with biotin by incubation of cells 
in 1× PBS containing 0.25 mg/ml EZ-Link Sulfo-NHS-SS-Biotin for 
30 min on ice. To detect localization of PDG FRα specifically at the 
cell surface upon ligand addition, cells were stimulated with 50 ng/ml 
PDGF-AA for the indicated times before biotin labeling. To detect in-
ternalized PDG FRα, cells were stimulated after labeling with biotin, 
and biotinylation of proteins at the cell surface was removed by treat-
ment with glutathione-stripping solution (50 mM reduced glutathione, 
150 mM NaCl, 70 mM NaOH, 1.25 mM MgSO4, 1.25 mM CaCl2, and 
1 mM EDTA, pH 8.5) for 10 min on ice. For total amounts of bioti-
nylated PDG FRα receptor, the same procedure was applied, except for 
stripping of biotin from cell surface proteins. SDS-PAGE and WB analy-
ses were performed with the rabbit anti–PDG FRα antibody (Abcam).
Statistical analysis
Statistical analyses represent the means of at least three independent 
experiments. Error bars represent standard errors of the mean (SEM; 
n = 3). P-values were calculated using the Student’s t test, if not spec-
ified: *, P < 0.05; **, P < 0.01; ***, P < 0.001; n.s., not significant.
Online supplemental material
Fig. S1 shows that Dox treatment itself does not affect PDG FRα 
signaling in WT NIH3T3 cells and that PDG FRα is up-regulated at 
the protein level in growth-arrested cells depleted for IFT20. Fig. S2 
shows the functional and biochemical interdependence of IFT20 and 
c-Cbl on the protein level and that the effect of IFT20 depletion on 
Cbl stabilization is not solely a consequence of ciliary loss. Fig. S3 
shows that IFT20, c-Cbl, and Cbl-b interact as indicated by MS and 
size-exclusion chromatography; that Dox treatment itself does not affect 
PDG FRα localization to the plasma membrane; and that codepletion of 
c-Cbl and Cbl-b leads to localization of GFP-tagged PDG FRα to the 
plasma membrane and prominently confined in puncta along extensive 
cellular protrusions. Table S1 shows MS–based analysis of proteins in-
teracting with FLAG–IFT20.
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